Pliant Therapeutics Future Growth
Future criteria checks 2/6
Pliant Therapeutics's earnings are forecast to decline at 0.5% per annum while its annual revenue is expected to grow at 64.7% per year. EPS is expected to grow by 6.9% per annum. Return on equity is forecast to be -76.8% in 3 years.
Key information
-0.5%
Earnings growth rate
6.9%
EPS growth rate
| Pharmaceuticals earnings growth | 21.1% |
| Revenue growth rate | 64.7% |
| Future return on equity | -76.8% |
| Analyst coverage | Good |
| Last updated | 12 Mar 2024 |
Recent future growth updates
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings
Jan 21
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?
Dec 17Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow
Dec 02Pliant Therapeutics: An Early Stage Company With Important Collaborations
Nov 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3 | -271 | -231 | -215 | 11 |
| 12/31/2025 | 6 | -241 | -195 | -195 | 13 |
| 12/31/2024 | 2 | -201 | -175 | -176 | 14 |
| 12/31/2023 | 2 | -161 | -117 | -116 | N/A |
| 9/30/2023 | 4 | -155 | -124 | -122 | N/A |
| 6/30/2023 | 5 | -144 | -106 | -105 | N/A |
| 3/31/2023 | 10 | -133 | -106 | -104 | N/A |
| 12/31/2022 | 10 | -123 | -96 | -95 | N/A |
| 9/30/2022 | 10 | -113 | -85 | -83 | N/A |
| 6/30/2022 | 10 | -109 | -89 | -87 | N/A |
| 3/31/2022 | 7 | -103 | -85 | -82 | N/A |
| 12/31/2021 | 8 | -97 | -77 | -75 | N/A |
| 9/30/2021 | 10 | -92 | -74 | -72 | N/A |
| 6/30/2021 | 13 | -81 | -67 | -65 | N/A |
| 3/31/2021 | 15 | -75 | -40 | -38 | N/A |
| 12/31/2020 | 42 | -42 | -39 | -37 | N/A |
| 9/30/2020 | 94 | 18 | 15 | 16 | N/A |
| 6/30/2020 | 90 | 19 | 16 | 17 | N/A |
| 3/31/2020 | 86 | 20 | -6 | -5 | N/A |
| 12/31/2019 | 57 | -7 | -4 | -3 | N/A |
| 3/31/2019 | N/A | -43 | -33 | -32 | N/A |
| 12/31/2018 | N/A | -35 | -31 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PLRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PLRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PLRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PLRX's revenue (64.7% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: PLRX's revenue (64.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PLRX is forecast to be unprofitable in 3 years.